21 abril 2016

J&J CEO Alex Gorsky summed up the quarter in general terms: "Our pharmaceuticals business continues to deliver impressive levels of growth," Gorsky said .

Potential sales catalysts include:


* DARZALEX for treating double refractory multiple myeloma .


* YONDELIS for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma .


Both drugs were approved in the fourth quarter.


******************************************************

Johnson & Johnson Boosts Guidance on Strong 1st-Quarter Results .


The healthcare conglomerate finally overcame currency impacts to produce top- and bottom-line growth.


Jnj LoveAmong healthcare companies, it's hard to find a match for Johnson & Johnson (NYSE:JNJ). Its impressive scope encompasses the over-the-counter consumer remedy market as well as the medical device arena, but J&J's biggest source of growth lately has come from the pharmaceutical space. Even as it works to compete against Pfizer (NYSE:PFE) and other big pharma names, Johnson & Johnson has had to fight against the strength of the U.S. dollar and its downward impact on its financial results.

Coming into Tuesday's first-quarter financial report, investors in Johnson & Johnson had hoped the company would be able to get things moving in the right direction again, and positive results on sales and earnings per share showed its success in doing so. Let's take a closer look at Johnson & Johnson's latest results and what you should learn from them.

J&J has a good prognosis
Johnson & Johnson's first-quarter financials showed some positive signs that investors haven't seen in a long time. Revenue for the quarter inched upward by 0.6% to $17.48 billion, exactly matching the consensus forecast among investors, but more importantly finding a way to produce any growth at all. Adjusted net income was up 6% to $4.69 billion, and that produced adjusted earnings of $1.68 per share, beating analyst estimates by $0.03 per share.

...